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Abstract: Liver metastasis is the main cause of mortality related to colorectal cancer. 
CXCR4 is necessary for the outgrowth of colon cancer micrometastases. In oncology, it has 
been d  emonstrated that several human tumors release lactate dehydrogenase (LDH) into the 
  circulation. CXCR4 gene expression and serum LDH levels are often increased in patients with 
colorectal cancer. Despite technological advances in cancer therapy, five-year overall survival is 
still around 50%. Therefore, better treatment needs to be developed. RNA interference (RNAi) 
is a modern and powerful tool for inhibition of gene expression. However, the rate-limiting step 
in this technology is effective delivery of RNAi agents. We have investigated a novel strategy of 
CXCR4 siRNA therapy and its effect on serum LDH levels in a BALB/C mouse model of col-
orectal cancer metastasis to the liver. Hepatic metastasis was established by injecting a CT26.WT 
mouse colon carcinoma cell line via the tail vein. Our results demonstrated that CXCR4 siRNA/
dextran-spermine nanoparticles achieved high silencing efficiency with low toxicity. Favorable 
localization of the nanoparticles was confirmed with CXCR4 gene expression in the liver, that 
was correlated with serum LDH levels. More research will be needed to determine the effect 
of CXCR4 silencing on serum LDH levels, which may be a useful marker for predicting liver 
metastasis in colorectal cancer.
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Introduction
Colorectal cancer is the third most common cancer after breast and lung.1 Death from 
colorectal cancer often results from liver metastases. Despite extensive research into the 
biology of cancer progression, the molecular mechanisms involved in metastasis of col-
orectal cancer are not well characterized.2 In cancer patients, serum lactate   dehydrogenase 
(LDH) levels are often increased, and high serum LDH levels have been linked with 
poor postoperative outcome, as well as failure of radiotherapy and chemotherapy in sar-
comas, lymphomas, and carcinomas, including colorectal cancer.3 Recent studies show 
that chemokines and their receptors are an important factor in organ-selective metastasis 
and that these are major regulators of cell trafficking and adhesion. Specific chemokines 
produced and released by target organs attract tumor cells with specific corresponding 
receptors, resulting in site- and/or organ-specific cancer cell migration and metastasis.4 
Among the chemokines, CXCR4 has an important role in the spread of colorectal and 
breast cancer. Accordingly, silencing of the CXCL12-CXCR4 interaction has shown 
marked inhibition of metastasis in tumor animal models.5,6Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Recently, the technology of RNA silencing, the process 
triggered by siRNA molecules, is poised to have a major impact 
on the treatment of human disease, particularly   cancer, and 
can be delivered to a wide range of organs. siRNA is currently 
being evaluated in clinical trials as a potential therapy for a 
range of inherited diseases.7,8 However, despite the high thera-
peutic potential of siRNA, its application in the clinical setting 
is limited due to problems with stability in blood and methods 
for effective delivery of chemotherapeutic RNAi agents.9
Recently, we have reported on a novel cationic polymer, 
dextran-spermine, a new biodegradable polycation based on 
natural components developed for gene delivery.   Effective 
transfection has been obtained using this   polycation for a vari-
ety of genes, cell lines, and tissues in vitro and in vivo.11–13 The 
aim of this study was to investigate the   correlation between 
expression of CXCR4 and serum LDH levels in colorectal 
cancer metastasis to the liver by using a different strategy 
for CXCR4 siRNA therapy.
Materials and methods
Materials
HT29, CT26.WT cell lines were purchased from the   American 
Tissue Culture Collection. SiGENOME-ON-TARGET plus 
SMART pool duplex CXCR4 in vitro (Genbank accession 
number NM-003467), siRNA1 Sense GAAGCAUGACG-
GACAAGUAUU; siRNA2.
Sense,  GGCCUUAUCCUGCCUGGUAUU; 
siRNA3 Sense, UAAC UACACCGAGGAAAUGUU; 
and siRNA4 Sense CAAGCAAGGG UGUGAGUUUUU, and 
in vivo individual siRNA duplex CXCR4 I (Genbank Acces-
sion number BC098322), Sense ACCAACAGUCAGAGGC-
CAAUU Catalog number LEEIG-000534, siRNA duplex 
CXCR4 II Sense GGUCAUGGGUU   ACCAGAAGUU 
Catalog number LEEIG-000536 and CXCR4 ON-TARGET 
plus a siCONTROL nontargeting pool were purchased from 
Dharmacon RNA Technologies (Lafayette, CO, USA). 
Dextran-spermine (FI-4/12A) was gifted from the University-
Hadassah Medical School, Jerusalem, Israel. Other chemical 
reagents used in our study were RPMI (Sigma Aldrich, St. 
Louis, USA), fetal bovine serum (PAA, Yeovil, UK), trypsin-
EDTA 1X (PAA), MTS kit (Promega, Madison, USA), Trizol 
reagent (Invitrogen, Carlsbad, USA), DNAse I kit (Sigma-
Aldrich), first-strand cDNA synthesis kit (K1612 Fermentas, 
Burlington, Canada), Quantitect SYBR Green RT-PCR one-
step kit (Qiagen, Hilden, Germany), rabbit polyclonal to 
CXCR4 (ab2074, Abcam, Cambridge,UK), goat anti-rabbit 
IgG FITC-labeled (Anaspec, CA, USA), LDH optimized 
assay kit (Anaspec), and Triton X-100 (Sigma-Aldrich).
Preparation of polysaccharide-oligoamine 
conjugates
A solution of oxidized polysaccharide 2 g in 200 mL double-
distilled water was slowly added over 5–7 hours to a basic solu-
tion containing a 1.5 equimolar amount of the corresponding 
oligoamine dissolved in 100 mL of borate buffer (0.1 M, pH 11). 
The mixture was gently stirred at room temperature for 24 hours. 
Reduced amine-based conjugates were obtained after reducing 
the amine conjugates with excess NaBH4 (2 g) added to the 
mixture at room temperature for 48 hours. The reduction was 
repeated with an additional amount of NaBH4 with stirring for 
24 hours under the same conditions. The mixture was dialyzed 
against double-distilled water (6 × 5 L) at 4°C, using 3500 
cutoff cellulose tubing (Membrane Filtration Products, Inc, San 
Antonio, TX). The resulting light-yellow solution was dialyzed, 
followed by freeze-drying to obtain a yellowish reduced amine-
based conjugate with an overall yield of 50%.16,17
Preparation and characterization  
of CXCR4 siRnA/  dextran-spermine 
nanoparticles
The formation of CXCR4 siRNA/dextran-spermine 
  nanoparticles was performed by mixing CXCR4 siRNA 
and dextran-spermine at various weight ratios in aqueous 
  solution. Briefly, 5 µg of CXCR4 siRNAs I and II was 
added to 50 µL of RNase free water and the solution was 
pipetted up and down 3–5 times, then placed in an orbital 
mixer for 10   minutes at room   temperature. The same volume 
of RNase-free water   containing 5, 10, 15, 20, and 25 µg of 
dextran-  spermine was placed in an orbital mixer for 10 min-
utes at room   temperature. The solution was gently agitated 
for 30 minutes to form self-assembled siRNA/dextran-
spermine complexes. Stability and structural characterization 
of CXCR4 siRNAs was confirmed by transmission electron 
microscopy (TEM), a particle size analyzer (Nanophox/ 
Sympatecs GmbH, Clausthal-Zellerfeld, Germany), and a 
zeta size analyzer (Malvern, Worcestershire, UK). Structural 
determination of the nanoparticles was done using TEM. For 
TEM, 100 µL of the sample was kept on a copper grid for five 
minutes, excess solution was blotted off using filter paper, 
and the copper grids were air-dried for five minutes.
MTs assay in hT29 and CT26.WT cells
HT29 and CT26.WT cells were seeded into 96-well plates 
at an initial cell density of 4 × 103 cells/well in a final volume 
of 100 µL medium per well. After 24 hours, HT29 cells were 
treated with 30 µg/mL dextran-spermine, dextran-hexamine, 
and pullulan-spermine. CT26.WT cells were also treated with Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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different concentrations of siRNA control (2000 ng/mL), 
CXCR4 siRNAs I and II, and CXCR4 siRNA/    dextran-
spermine (3000 ng/mL). After 48 and 72 hours, an aliquot of 
20 µL of combined solution of a tetrazolium compound MTS, 
was added into each well and incubated for an additional 
four hours, and the absorbance at 490 nm was measured by 
Thermo Lab Systems, Cheshire, England.
Transfection and detection 
of CXCR4 siRNA efficiency
CT26.WT mouse colon carcinoma cells were grown in 
RPMI-1640 supplemented with 10% fetal bovine serum and 
incubated at 37°C with 5% CO2. The siRNAs were   transfected 
into HT29 cells at a final concentration of 100 ng/mL using 
dextran-spermine. To optimize the efficiency of siRNA, 
CT26.WT cells were transfected with different doses of 
in vivo naked siRNAs CXCR4 I and II (started from 10, 50, 
100, and 200 ng/mL) after 24 hours.
RT-PCR for siRnA optimization
Total RNA was isolated using Trizol reagent and reverse-
  transcribed to cDNA using a first-strand cDNA synthesis kit 
according to manufacturer’s instruction. The mouse CXCR4-
specific primers for 105 bp were 5’-AAGCAAGGATGTGACT-
TCGAGAG and 5’-  CGAGGAAGGCATAGAGGATGG 
  (GenBank accession number BC098322). Primers for mouse 
ß-actin 146 bp were 5’-TGTTACCAACTGGGACGA-
CATG-3’ and 5’-TCAAACATGATCTGGGTCATCTTTTC 
(Genbank accession number EF095208). The annealing tem-
perature was 57°C and the reaction proceeded for 35 cycles. 
To control for the presence of intact RNA, real-time (RT) 
polymerase chain reaction (PCR) for mice ß-actin was 
performed under the same conditions, as described earlier. 
Various concentrations of siRNA were tested by RT-PCR 
from 10, 50, 100, and 200 ng/mL. The PCR products were 
electrophoresed through 1% agarose gel.
immunocytochemistry on hT29 cells
HT29 cells were grown on cover slips. After 24 hours, 
HT29 cells were treated with 100 ng/mL CXCR4 siRNAs, 
CXCR4 siRNA/dextran-spermine and a nontarget siRNA 
  control. After 72 hours, cells were fixed with phosphate-
  buffered saline containing 3% paraformaldehyde for 15 minutes 
at 37°C. After three washes with phosphate-buffered saline, 
HT29 cells were treated with 0.2% Triton X-100 in phosphate-
buffered saline for 10 minutes at 4°C to permeabilize the fixed 
cells and thereby facilitate access to the antibody. Cells were 
blocked for 60 minutes at 37°C in blocking buffer   containing 
2% bovine serum albumin in phosphate-buffered saline. 
The cells were then incubated with rabbit polyclonal CXCR4 
antibody diluted 1:100 in blocking buffer for overnight at 4°C, 
washed three times in phosphate-buffered saline for 10 min-
utes, incubated with FITC-conjugated goat-antirabbit IgG at a 
  concentration of 1 µg/mL for 60 minutes at 37°C in the dark, 
then washed again in phosphate-buffered saline three times 
for five   minutes, rinsed in water, and mounted with mounting 
medium before examination by fluorescence microscopy.
Animal experiments
Female BALB/C mice aged 7–8 weeks (obtained from the 
Institute of Medical Research in Malaysia) were divided into 
six groups, with six mice per group. Group 1 mice were given 
injections of 1 × 105 CT26.WT mouse colon carcinoma cells 
transfected with nonspecific control siRNA duplexes, and 
were subsequently given injections of the control siRNA 
twice weekly. Group 2 mice were given intravenous injections 
through the tail vein of 1 × 105 CT26.WT cells transfected 
with CXCR4 siRNA I and II/dextran spermine (150 ng/g body 
weight) at 48 hours before injection. The Group 3 mice were 
injected with CT26.WT cells treated with CXCR4 siRNA 
I and II 150 ng/g body weight. Mice in Group 2 and Group 3 
were not treated after the   administration of tumor cells. Group 
4 mice were given intravenous injections through the tail vein 
of 1 × 105 CT26.WT cells transfected with CXCR4 siRNA I 
and II, and Group 5 were given CXCR4 siRNA I and II/  dextran-
spermine 48 hours before injection of CT26.WT cells. Mice in 
Group 4 were treated with CXCR4 siRNA I and II, and mice 
in Group 5 were treated with CXCR4 siRNA I and II/dextran-
spermine twice weekly after injection of CT26.WT cells. 
Groups 2, 3, 4, and 5 were given CXCR4 siRNA I and II 
150 ng/g body weight. Group 6 animals were given nonspecific 
control siRNA duplexes by twice-weekly injection through the 
tail vein without prior injection of CT26.WT cells. In Groups 
A, B, C, D and E, mice were injected with 2 × 104 CT26.WT 
cells subcutaneously into the lateral abdominal surface near 
the left side of the pelvis for two purposes, ie, to induce further 
colorectal cancer with limited effect on important organs, in 
particular the heart, liver, and lungs, and to ensure growth of 
tumor cells in vivo. The mice were sacrificed after 35 days.
RnA preparation and RT reverse 
transcription PCR
Total RNA was isolated from frozen liver tissues (50 mg) using 
Trizol reagent according to the manufacturer’s instructions. 
RT quantitative reverse transcriptase PCR was performed 
using an RT-PCR RotorGene 3000 machine (Corbett, Sydney, Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Australia), with a Quantitect SYBR Green RT-PCR one-step kit 
as instructed by the manufacturer. Briefly, 500 ng of RNA was 
placed into a 20 µL reaction volume containing 0.2 µM of each 
primer, 10 µL of Syber Green I RT-PCR one-step master mix, 
and 0.2 µL of reverse transcriptase. A typical protocol included 
reverse transcription at 50°C for 30 minutes and a denaturation 
step at 95°C for 15 minutes, followed by 40 cycles with 94°C 
denaturation for 15 seconds, 57°C annealing for 30 seconds, and 
72°C extension for 30 seconds. Melt (72–95°C), hold 45 sec-
onds on the first step, hold five seconds on next steps, Melt A 
(FAM). To confirm amplification specificity, the PCR products 
were subjected to a melting curve analysis. Negative controls 
containing water instead of RNA were run concomitantly to 
confirm that the samples were not cross contaminated.
histostaining of liver in BALB/C mice
Hematoxylin and eosin staining was done to evaluate the 
presence or absence of tumors at the end of the experiments 
on day 35. Animal organs and tumors were formalin-fixed and 
paraffin-embedded. Tissue sections were washed twice with 
xylene for three minutes, rehydrated in ethanol (100% twice 
for three minutes, 90% for two minutes, 80% for two minutes, 
70% for two minutes), and the sections were then stained with 
hematoxylin and eosin, deparaffinized in xylene, rehydrated, 
and mounted in accordance with standard procedures.
serum LDh measurement
Blood samples for serum LDL measurement were obtained 
by heart puncture at 35 days and allowed to clot. LDL 
measurements were made using an LDH optimized assay 
kit (Roche Diagnostics, Mannheim, USA), according to the 
manufacturer’s instructions. LDH activity was expressed 
as U/L.
Results
Characterization of CXCR4 siRnA  
i and ii/dextran-spermine nanoparticles
In this study, TEM was used to determine the morphology of 
the formed nanoparticles after eight hours of preparation using 
CXCR4 siRNAs I and II/dextran-spermine in various µg ratios 
from 1:1 to 1:5. At the 1:5 ratio, nanoparticles formed and the 
particles repelled one another, thereby preventing particles 
from aggregating. CXCR4 siRNAs/dextran-spermine formed 
small round particles (Figure 1). Particle size was automatically 
calculated using particle sizer analysis/  Nanophox after keep-
ing one month at -80°C and freshly preparation. Particle size 
was obtained (10 × 12.42 nm ± 2.09), (50 × 26.77 nm ± 2.73), 
and (90 × 57.62 nm ± 2.51). This experiment was done three 
Figure  1  Transmission  electron  microscopy  showing  the  morphology  of 
nanoparticles.
times and each time was repeated 40 times. The zeta potential 
of surface charge of three nanoparticles was automatically 
calculated (39.8 ± 0.2 mV).
Cell viability in hT29 and CT26.WT cells
Viability assessed in HT29 cells transfected with dextran-
spermine 15 µg/mL after 24 hours was 0.82 ± 0.03, after 
48 hours was 0.81 ± 0.0.06, and after 72 hours was 0.71 ± 0.01, 
 ( Figure 2A). CT26.WT cells transfected with nontarget con-
trol siRNA after 48 hours at a concentration of 2000 ng/mL 
was 0.84 ± 0.01 (Figure 2B), and CXCR4 siRNAs I and II and 
CXCR4 siRNAs I and II/dextran-spermine after 48 hours at a 
concentration of 750 ng/mL were 0.85 ± 0.02 and 0.72 ± 0.04, 
respectively (Figure 2C). These results indicated that dextran-
spermine and CXCR4 siRNAs have no effects on adherent cell 
growth at 15 µg/mL. This lack of cytotoxicity also implies a 
limited systemic effect on normal cells in vivo.
immunocytochemistry on hT29 cells
To confirm the RT-PCR experiments, the protein level of 
CXCR4 in HT29 (as a positive control) was characterized 
by immunocytochemistry. The results showed that CXCR4 
receptors with higher staining in HT29 transfected with the 
nontarget siRNA control (Figures 3A–D), moderate staining 
in HT29 cells transfected with naked CXCR4 siRNAs, and 
weak staining in HT29 transfected with CXCR4 siRNA/
dextran-spermine complex.
CXCR4 expression, serum  
LDh levels, and histology
Total RNA was isolated from the liver 35 days after tumor cell 
injection in the six groups of animals. RT reverse transcription 
PCR was performed on the RT-PCR machine RotorGene Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 2 Viability in hT29 cells. A) Viability was assessed in hT29 cells transfected with dextran-spermine at a concentration of 15 µg/mL. B) CT26.WT cells transfected 
with nontarget control siRnA. C) CT26.WT cells transfected with CXCR4 siRnAs i and ii and with CXCR4 siRnA/dextran-spermine.
3000, and analysis of CXCR4 and β-actin expression was 
performed using the delta-delta CT method. A   standard curve 
was done with a dilution of 1:2. CXCR4 efficiency was 1.34 
with an R^2 value of 0.99; β-actin efficiency was 1.04 with 
an R^2 value of 0.99. Based on one-way analysis of vari-
ance and a least significant difference post hoc test, there 
were significant differences between the groups at the level 
F = 66.63 (P = 0.000). As illustrated in Figures 4A and 4B, 
mice in Groups A and C showed increased CXCR4 expression 
level which was higher than for Groups B, C, and E, but no 
significant differences were found between Group E and 
Group B (P . 0.05). These results indicated that inhibition 
with CXCR4 siRNA/dextran-spermine was more   efficient 
than by naked CXCR4 siRNA, and also post-  treatment 
  follow transfection of tumor cells more efficiently than just 
transfection cell treatment with naked CXCR4 siRNA or 
CXCR4 siRNA/dextran-spermine.
To examine the effects of CXCR4 siRNA naked or 
nanoparticles on serum LDH levels in the animals, we 
compared LDH levels between the groups using one-way 
analysis of variance and an LDH post hoc test (Figure 5). 
The results indicated that there were significant differ-
ences between the groups (F = 20.27, P = 0.0000). The 
results   indicated that just Group E had received CT26.WT 
  transfected with CXCR4 siRNA/dextran-spermine plus 
injection of CXCR4 siRNAs I and II/dextran-spermine twice 
weekly. The level of serum LDH was approximately that 
of Group F which had not received any cells or treatment. 
CXCR4   siRNAs I and II/dextran-spermine was more efficient 
in reduction of CXCR4 expression and bringing LDH levels Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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nearer to normal than naked siRNA. These results were fur-
ther confirmed by hematoxylin and eosin staining 35 days 
after tumor cell injection. Hematoxylin and eosin staining 
of the liver showed that numbers of infiltrative lymphocytes 
along with cancer cells between the hepatic parenchyma and 
portal vein were lower in Group E compared with the other 
groups (Figures 6A–H).
Discussion
This study evaluated different methods of siRNA target-
ing CXCR4 therapy for colorectal metastasis to the liver 
in vivo. Efficient and safe in vivo delivery of short siRNA 
which is essential for therapeutic applications has not been 
established.13 Here dextran-spermine was identified as an 
effective carrier for siRNA. Two siRNAs were chosen specifi-
cally for CXCR4 mRNA so that the sequences were similar 
between mice and humans, with no similarity to other genes. 
Eliyahu et al compared the cytotoxicity of dextran-spermine 
with well established polyplexes and lipoplexes. They reported 
dextran-spermine being the least cytotoxic.14,15 In this experi-
ment, dextran-spermine was not toxic at 15 µg/mL by MTS and 
CXCR4 siRNAs at 3000 ng/mL. With respect to the low ratio 
of 1:5 and low doses of siRNAs used to make the nanoparticles, 
small size of nanoparticles 57.62 nm ± 2.51 with high zeta 
potential 39.8 mV ± 0.2. We expected that the   nanoparticles 
could be efficiently internalized into cells with lowest toxicity. 
Immunocytochemistry of in vitro CXCR4 siRNA/  dextran-
spermine showed high protein expression in control on HT29 
cell membrane, moderate with naked siRNAs I and II, and 
weak with CXCR4 siRNA/dextran-spermine nanoparticles. 
Various treatment combinations of siRNAs I and II of CXCR4 
with and without dextran-spermine were compared in experi-
mental metastatic animal models of CT26.WT cells. In vivo 
study demonstrated that self-assembled siRNAs I and II/
dextran-spermine and treatment twice weekly achieved better 
inhibition of CXCR4 expression than naked siRNAs I and II 
in vivo (Figure 4). The highest CXCR4 expression (8.09 ± 0.8 
fold) and serum LDH (85.37%) was in Group A mice (injected 
tumor cells transfected control siRNA) and the lowest CXCR4 
expression (2.49 ± 0.04 fold) and serum LDH (27.23%) was in 
Group E. The level of serum LDH was proportional to CXCR4 
expression in the different groups (Figure 5). There was a 
significant correlation between CXCR4 expression and LDH 
level (Pearson correlation coefficient R = 0.861, P = 0. 000). 
It has been reported that when suspensions of cancer cells are 
injected via the portal vein or spleen in animals, the cells are 
rapidly attacked by the host immune system and also suffer 
A
B
Figure 3 immunocytochemistry on hT29. Protein level of CXCR4 in hT29 was 
characterized by immunocytochemistry using rabbit polyclonal CXCR4 antibody 
and FiTC-conjugated goat-antirabbit igg. A) negative control with deletion of the 
primary antibody. B) hT29 transfected with nontarget siRnA control. C) hT29 
transfected with CXCR4 siRnA i and ii. D) hT29 transfected with CXCR4 siRnA/
dextran-spermine.
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from hemodynamic forces.16 In fact, although the majority 
of injected cancer cells were found to be arrested in the liver 
sinusoid several minutes after injection, the vast majority of 
injected cancer cells were disseminated or no longer viable at 
24 hours. Finally, only 1% of injected cancer cells survive in 
the liver.17,18 Hematoxylin and eosin staining of the liver shows 
that infiltrative lymphocytes along with cancer cells between 
hepatic parenchyma and portal vein follow CT26.WT cell 
metastasize to the liver. There were high rates of metastases 
in Group A, low rates in Groups C and D, and hardly any 
metastases in Groups B and E.
In  this  study  we  used  different  strategies  for 
CXCR4   silencing. Combining CXCR4 siRNAs I and II 
with nanoparticle technology inhibits CXCR4 gene expres-Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 6 histostaining of liver of mice: effect of CXCR4 siRnAs on inhibition of colorectal cancer metastasis to liver in vivo. A) h and e staining of tumor show growth 
and angiogenesis in group A. B) H and E staining of liver (original magnification 10×) in Group F without injection of tumor cells; in this group there were no infiltrative 
lymphocytes. C) H and E staining (original magnification 40×) of liver in group F. D) H and E staining of liver (original magnification 40×) in group A along with subcutaneous 
injection of tumor cells through tail vein, showing a lot infiltrative lymphocytes between the hepatic parenchyma and portal vein following metastasis of tumor cells to the 
liver. E) H and E staining (original magnification 40×) of liver in group B. F) H and E staining (original magnification 40×) of liver in group C. G) h and e staining (original 
magnification 40×) of liver in group D. H) Hematoxylin and eosin staining (original magnification 40×) of liver in group C. Metastases in groups A, B, C, D, and e were 
compared with group e. 
Abbreviation: h and e, hematoxylin and eosin.Cancer Management and Research
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sion more than naked CXCR4 siRNAs I and II. Inhibition 
of CXCR4 expression at the mRNA level by a combination 
of two siRNAs with dextran-spermine was correlated with 
serum LDH in a model of colorectal cancer.
In conclusion, dextran-spermine demonstrated improved 
transfection efficiency in siRNA therapy. More research is 
needed to determine the effect of CXCR4 silencing on serum 
LDH levels, which may be a useful marker to predict liver 
metastasis in colorectal cancer.
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